SH3 and SAM domains are protein interaction motifs that are predominantly seen in signaling molecules, adaptors, and scaold proteins. We have identi®ed a novel family of putative adaptor genes that includes HACS1. HACS1 encodes a 441 amino acid protein that is dierentially expressed in hematopoietic cells and has restricted expression in human tissues. Its SH3 domain is most similar to the same motif in Crk and its SAM domain shares homology with a family of uncharacterized putative scaold and adaptor proteins. HACS1 maps to human chromosome 21q11.2 in a region that is frequently disrupted by translocation events in hematopoietic malignancies. Polyclonal antibodies against HACS1 recognized a 49.5 kDa protein whose mRNA is expressed in human immune tissues, bone marrow, heart, lung, placenta and brain. Cell lines and primary cells from acute myeloid leukemias and multiple myeloma patients express HACS1. Immunostaining and cellular fractionation studies localized the HACS1 protein predominantly to the cytoplasm. Oncogene (2001) 20, 5373 ± 5377.
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Keywords: myeloma; adaptor protein; hematopoietic; SAM domain; SH3 domain Sterile a motifs (SAM) are 70 amino acid interaction domains present in diverse proteins including Eph receptors (Stapleton et al., 1999) , ETS transcription factors (Kyba and Brock, 1998) , the p53 gene family (Arrowsmith, 1999) , the Shank family (Sheng and Kim, 2000) , and signaling molecules such as tyrosine and serine/threonine kinases (Tu et al., 1997) . Although SAM domains are able to self-associate, SAM domains of various proteins also interact heterotypically with other proteins. For example, the three tandem SAM domains of LIP (LAR-interacting protein) interact with protein tyrosine phosphatase LAR, a protein that does not contain a SAM motif (Serra-Pages et al., 1995) and the SAM domain of EphB1 receptor tyrosine kinase binds to the SH2 domain of the signaling protein Grb10 (Stein et al., 1996) . Several cytoplasmic scaold proteins such as members of the Shank family have SAM domains in addition to an SH3 signaling module. SH3 domains are known to mediate interactions of proteins in a number of signal transduction pathways by binding to proteins containing proline rich motifs (Pawson, 1995) . The presence of SAM and SH3, or SAM and SH2 in a protein is often indicative of adaptor or scaolding functions.
In our transcriptional study of genes expressed in multiple myeloma (manuscript in preparation), we identi®ed a clone that by Blast analysis in dbEST appeared to have restricted expression in hematopoietic cells such as macrophages, hematopoietic progenitor cells, T cells, germinal center B cells, and in hematopoietic tissues such as lymph node, thymus, and spleen. Library screening and full length sequencing of cDNA clones from plasma cell leukemia and hematopoietic progenitor libraries revealed that these clones encode a novel gene which we called HACS1 (Hematopoietic Adaptor Containing SH3 and SAM domains) (Figure 1 ). Northern analysis showed that this gene is expressed as a 2.2 kb transcript in human immune tissues and hematopoietic cell types including normal human bone marrow, acute myeloid leukemia, and multiple myeloma cell lines and patient samples (Figure 2a) . A human tissue blot also demonstrated low level expression in other tissues such as heart, brain, placenta and lung (Figure 2a ). Preliminary analysis of primary patient samples (n=9) also demonstrated expression in acute myeloid leukemia (four of seven), but not in single samples from acute lymphoblastic leukemia or chronic myeloid leukemia patients (data not shown).
HACS1 encodes a 441 amino acid protein containing two domains frequently associated with signaling molecules (Figure 2b ). An SH3 motif is predicted in the middle half of the protein and a SAM domain is located toward the C-terminal end. The SH3 motif shares 39% homology with Crk. There are three predicted consensus nuclear localization signals on amino acid positions 136 ± 152, 297 ± 303 and 357 ± 363. A tyrosine kinase phosphorylation motif is predicted at amino acid 221 ± 228. An amino acid sequence homology search revealed that HACS1 is a member of a novel gene family of putative adaptors and scaold proteins. This family includes two uncharacterized hypothetical proteins dJ753P9.2 (here- Figure 1 Alignment of deduced amino acid sequence of HACS1 and related proteins. Human HACS1 (Acc. no. AF218085), mouse HACS1, hypothetical protein dJ753P9.2 (Acc. no. CAB41255) and KIAA0790 (Acc. no. BAA34510) amino acid sequences were aligned using Clustal W1.8 (http://dot.imgen.bcm.tmc.edu:9331/multi-align/multi-align.html) and shaded using Boxshade 3.21 (http://www.ch.embnet.org/software/BOX_form.html). The amino acid sequence of the putative mouse ortholog of HACS1 was deduced by assembling EST contigs using the Tigem server (http://gcg.tigem.it/cgi-bin/uniestass.pl). The complete nucleotide sequence of HACS1 was determined from a full length clone isolated from a promyeloblast cDNA library (Claudio et al., 1998) . Noteworthy are two nucleotide dierences between the sequence of HACS1 and chromosome 21 segment HS21C006 sequence (AL163206.2). This sequence variation results in amino acid changes at position 20 (GAC coding for D in HACS1 but AAC coding for N in HS21C006) and at position 64 (TAC coding for Y but CAC coding for H in HS21C006). Whether these apparent polymorphisms (SNP) have functional implications on HACS1 protein is unknown because this region is not conserved in mouse HACS1. The SH3 and SAM domains are boxed. The 19-mer peptide (KLH-SDGTSNRDSFRLDDDGPYS) used to immunize rabbits to generate anti-HACS1 antibody is located just upstream of the SH3 domain after HACS2), and KIAA0790. These proteins show strong similarity throughout, but highest homology is observed in both the SH3 and SAM domain regions (Figure 1) . A sequence search in dbEST indicated that HACS2 transcripts also have a hematopoietic expression pattern. ESTs that matched HACS2 were identi®ed predominantly in hematopoietic tissues such as human lymph node, germinal center B-cell, pediatric lymphoblastic leukemia cells, and chicken Bursa of Fabricius; suggesting that like HACS1, HACS2 may have an important hematopoietic role. KIAA0790 appears to be ubiquitously expressed based on the expression data for UniGene Cluster Hs. 12002. Its cellular expression in fetal liver and spleen, progenitor cells, macrophage, and T-cells, as indicated by Blast matches in dbEST, however, suggests that it may also play a role in hematopoiesis.
Analysis of genomic sequences from GenBank's high throughput genomic database (htgs) showed that the HACS1 sequence is contained in BAC clones from chromosome 21. HACS1 spans *50 kb and consists of at least 9 exons. HACS1 maps to human chromosome 21q11.2 in a region that is frequently disrupted by translocation events in hematopoietic malignancies (Mitelman et al., 1997) . Although there is no evidence that HACS1 plays a role in hematopoietic malignancy, Figure 2 Expression pattern of HACS1. (a) Northern hybridization. RNA from immune and multiple tissues and from myeloma, leukemia and prostate carcinoma cell lines were hybridized with HACS1 probe (nucleotide 783 ± 2218). Cell lines: NIH3T3 (mouse ®broblast), K562 (erythroleukemia), KG1 and KG1-a (myeloid leukemia), H929, U266, KMS11, OCI My5, ANBL6 (myeloma), DU145 and PC3 (prostate carcinoma), 293 (embryonal kidney), and Namalwa (Burkitt's lymphoma). (b) Western blot. Lysates from GST fusion constructs and myeloma cell lines were separated in 10% SDS ± PAGE. An anity puri®ed a-HACS1(1) antibody detected protein bands in constructs JOC1 and JOC17 that contain the antibody epitope, but not in JOC13 which lacks the epitope and in the GST construct used as negative control. The same a-HACS1(1) antibody detected a 49.5 kDa band in myeloma cell line OCIMy4, erythroid cell line K562, and promyeloblast KG1-a. Faint signals were detected in OCIMy5 and OCIMy7 myeloma cell lines only upon long exposure. A second antibody, a-HACS1(2), developed from the carboxy-terminal end of HACS1 protein also detected the same molecular weight protein in KG1-a and K562. Jurkat (acute T-cell leukemia) U266, OCIMy7, OCIMy5, OCIMy4, KMS11, H929 and ANBL6 (myeloma cell line). SUP-T1 (T cell lymphoblastic lymphoma) K562 (erythroleukemia), KG1-a (myeloid leukemia), Namalwa, Raji (Burkitt's lymphoma), EM2 (cell line from CML patient) COS-1 (monkey kidney) SAM domains can become oncogenic as in the case of the chimeric fusion of TEL transcription factor's SAM domain to bPDGF receptor (Golub et al., 1994) , AML1 (Golub et al., 1995) , c-Abl (Golub et al., 1996) and JAK2 (Lacronique et al., 1997) .
In vitro transcription and translation of the full length HACS1 cDNA produced a 49.5 kDa protein (data not shown), consistent with the predicted size of the protein based on amino acid calculations using the ExPASy server. A polyclonal antibody developed against a 19-mer peptide located just upstream of the SH3 motif (Figure 1 ) detected a protein of approximately 49.5 kDa in some hematopoietic cell lines. This antibody recognized puri®ed GST-HACS1 fusion proteins containing the epitope, but not in protein constructs lacking this site (Figure 2b ). High HACS1 protein expression was detected in erythroid cell line K562, progenitor cell line KG1-a and myeloma cell line OCIMy4. Western analysis of lysates from myeloma cell line OCIMy4 detected a slower migrating doublet protein band compared to the protein seen in KG1-a and K562. The dierences in protein migration and the nature of the extra band are as yet unclear. Another polyclonal antibody developed towards the carboxyterminal end also detected the same molecular weight protein in hematopoietic cell lines (Figure 2b ).
Immunocytochemistry staining of transiently transfected COS cells using anti-HACS1 antibody showed that HACS1 is localized in the cytoplasm (Figure 3) . In cellular fractionation studies, HACS1 was detected in the cytoplasm, although minimal expression was also observed in the nucleus (Figure 4) . As the majority of HACS1 protein is cytoplasmic, translocation to the nucleus, in addition to the presence of a nuclear localization motif within the protein, likely requires further signals. This hypothesis is supported by the observation that domains in HACS1 are found in both cytoplasmic and nuclear signaling proteins. Identi®ca-tion of binding partners of HACS1 will be required to shed further light on this function.
We hypothesize based on the presence of SH3 and SAM domains within the protein, that HACS1 may have a function analogous to other adaptor proteins that link signaling molecules in signal transduction cascades. For example, CrkL, a gene highly homologous to the oncogene adaptor Crk, associates with GCKR (also referred to as KHS1) in the cytoplasm through its SH3 motif to activate the SAPK/JNK pathway (Shi et al., 2000) . Additionally however, CrkL functions as a nuclear adaptor and transcriptional activator in Bcr-Abl expressing cells (Rhodes et al., 2000) . The presence of SH3 and SAM domains in Figure 3 Cytoplasmic localization of HACS1 protein by immuno¯uorescence (a) A COS-1 cell transfected with HA-tagged HACS1 is shown. Cytoplasmic staining is evident in the transfected cell using mouse monoclonal anti-HA antibody. An untransfected cell in the same ®eld is shown with only its nucleus stained. COS-1 cells were transfected with a pcDNA3.1 HAtagged full-length HACS1 plasmid using Lipofectamine. Cells were cultured for 24 h and then ®xed in 4% paraformaldehyde/ 1X phosphate buered saline (PBS)/ Ca 2+ Mg 2+ for 30 min at room temperature and permeabilized with 0.2% Triton X-100 in PBS for 10 min. The cells were incubated for 30 min at 378C with mouse monoclonal anti-HA antibody in 5% normal goat serum and 3% BSA. An Alexa 488 antibody was used for the secondary antibody (green). The nuclei were stained with propidium iodide (red). After washing the cells with 0.05% Triton X-100 in 1XPBS/ Ca Andrews and Faller (1991) was used to obtain the cellular fractions. Brie¯y, a hypotonic buer (10 mM HEPES, 1.5 mM MgCl 2 , 10 mM KCl, 10 mM NaPPi, 100 mM NaF, 0.5 mM DTT, and protease inhibitors) was added to the cells followed by dounce homogenization. The lysate was spun for 1 min at room temperature and the supernatant collected to obtain the cytoplasmic fraction. A high salt buer (20 mM HEPES, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM DTT, 10 mM NAPPi, 100 mM NaF, and protease inhibitors) was added to the remaining pellet and incubated at 48C for 1 h. The lysate was centrifuged for 5 min at 14 000 r.p.m. The supernatant collected was the nuclear fraction. The cytoplasmic and nuclear lysate fractions (20 mg/lane) were separated in a 10% polyacrylamide gel, transferred to PVDF membrane, and blotted with an anti-FLAG antibody. The membrane was stripped and reblotted using an anti-PARP antibody and an anti-Eps15 antibody to verify the eectiveness of the fractionation procedure. (b) Endogenous fractionation of HACS1 in K562 and KG1a cells. In each case, the cells were collected by centrifugation and washed twice with 1X PBS. The methodology for obtaining the fractions are as above. A second HACS1 antibody was generated using a GSTfusion protein containing the SAM domain and the C-terminal region of HACS1. The endogenous HACS1 in the K562 and KG1a lysates was detected using the SAM/C-terminus anti-HACS1 antibody. SAM/C-terminus HACS1 antibody recognizes amino acids 298 ± 441 (region just upstream of the SAM domain to the end of the protein). The anti-PARP antibody and an antiEps15 antibody were used as controls HACS1 and its mainly cytoplasmic localization suggest that, like CrkL, it may act as a cytoplasmic adaptor to mediate a signaling pathway. Whether it may have a dual function of regulating transcription as well, mainly because of the presence of nuclear localization signals within the protein, remains an interesting possibility.
